Molecular Partners Presents Updated Results of MP0250 in Patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting
Zurich-Schlieren, Switzerland, December 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage
biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today
announced a poster presentation at the American Society of Hematology 61st Annual Meeting in
Orlando, FL, highlighting the activity of its tri-specific DARPin® drug candidate, MP0250, in patients
undergoing treatment for multiple myeloma.
MP0250 is a first-in-class, tri-specific multi-DARPin® drug candidate neutralizing VEGF-A and HGF and is
binding to human serum albumin to increase plasma half-life. The unique mechanism of action of
MP0250 represents a new approach to targeting the tumor microenvironment and increase patients’
responses to already approved therapies for multiple myeloma, potentially even after progression.
“At present, anti-angiogenic agents are not part of treatment strategies in multiple myeloma, neither
alone nor in combination with approved agents,” commented Nicolas Leupin, Chief Medical Officer of
Molecular Partners. “MP0250 represents a unique and much-needed addition to the treatment
paradigm for patients with multiple myeloma. We believe that by treating one of the underlying
causes of the disease through targeting the tumor microenvironment, we can achieve durable and
deep responses in patients relapsing after or refractory to treatment regimens including bortezomib,
IMiDs or daratumumab. The response rate seen in this study, given the heavily pretreated patient
population involved, is very encouraging. We look forward to the generation of additional combination
data for MP0250 with relevant treatments to further detail the potential for this program.”